Regeneron stock: Piper Sandler raises target to USD 865.00

Published on 10/20/2026 at 16:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron reports third-quarter results on October 30, 2026. Regeneron stock costs EUR 710.10 on October 20, 2026 at 4:06 p.m. CEST in trading.

Target and reporting date

Piper Sandler raised its Regeneron target from USD 854.00 to USD 865.00 on October 19, 2026.
Regeneron will report third-quarter 2026 results on October 30, 2026.
Regeneron stock costs EUR 710.10 at Lang & Schwarz on October 20, 2026 at 4:06 p.m. CEST.

Isometrische 3D-Illustration einer Bioreaktor- und Zellkultur-Prozesskette in Pastellfarben — Regeneron Pharma US75886F1075 stellt ein isometrisches 3D-Diagramm der Bioreaktor-Wertschöpfungskette samt Zellkultur und Aufreinigung dar, Illustration mit AI erstellt.

Regeneron stock (ISIN US75886F1075) is facing a higher analyst target after Piper Sandler lifted its price objective to USD 865.00 from USD 854.00 on October 19, 2026, while retaining an Overweight rating, as reported by Markets Insider. Regeneron will publish its third-quarter 2026 results on October 30, 2026, according to Regeneron. At Lang & Schwarz, the stock was trading at EUR 710.10 on October 20, 2026 at 4:06 p.m. CEST.

Second-quarter revenue reached USD 4.29 billion

Regeneron generated USD 4.29 billion in revenue in the second quarter of 2026 and reported diluted earnings per share of USD 12.23. Net income attributable to common shareholders was USD 1.30 billion for the same period. The figures are reported in a period-specific financial overview carried by MarketBeat.

Nasdaq price remains below the yearly high

On the Nasdaq, Regeneron last traded at USD 798.80 on October 20, 2026 at 10:16 a.m. ET. The quotation was USD 16.76, or 2.14 percent, above the prior Nasdaq close of USD 782.04. Regeneron's 52-week range stood at USD 572.75 to USD 859.34, placing the latest Nasdaq price USD 60.54 below the high. Market capitalization was USD 82.2 billion and volume was 97,845 shares at that timestamp.

What does the higher target imply?

Piper Sandler's USD 865.00 target lies 8.29 percent above the Nasdaq price of USD 798.80 on October 20, 2026. Regeneron's price-to-earnings ratio was 19.76, while the company enters the October 30 reporting date with second-quarter operating figures already in view.

Comparison with peers

Regeneron: up 2.14 percent, price-to-earnings ratio 19.76, market capitalization USD 82.2 billion.

Eli Lilly and Company (NYSE, USD): up 4.81 percent, price-to-earnings ratio 43.57, market capitalization USD 1.2 trillion.

Gilead Sciences (Nasdaq, USD): up 1.37 percent, market capitalization USD 192.4 billion.

The euro quote stays central

The Lang & Schwarz quote puts the stock at EUR 710.10 on October 20, 2026 at 4:06 p.m. CEST, while the next company date is October 30, 2026. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.